Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 05, 2015 6:19 AM ET

Healthcare Providers and Services

Company Overview of AlloSource, Inc.

Company Overview

AlloSource, Inc. operates as a tissue bank that develops, processes, and distributes standard and customized precision allograft products to the medical community in the United States and internationally. The company offers precise bone, skin, soft-tissue, and custom-machined allografts for use in an array of life-saving and life-enhancing medical procedures. It provides osteobiologic grafts, including AlloStem, cellular bone allograft for general bone grafting applications; AlloFuse DBM that includes gel, paste, and putty bone graft substitutes; and AlloFlex, a cancellous bone allograft. The company also offers cancellous and structural general orthopedic grafts; spinal grafts, including ce...

6278 South Troy Circle

Centennial, CO 80111

United States

Founded in 1994





Key Executives for AlloSource, Inc.

Chief Executive Officer, President and Director
Chief Financial Officer and Vice President
Vice President of Operations
General Counsel and Vice President of Corporate Compliance
Chairman of Medical Advisory Board and Senior Medical Director
Compensation as of Fiscal Year 2014.

AlloSource, Inc. Key Developments

AlloSource Launches of AlloSkin AC

AlloSource announced the launch of AlloSkin AC, an acellular dermal allograft. The Centers for Medicare & Medicaid Services (CMS) also moved AlloSkin RT, a meshed human dermal graft, from the low-cost to the high-cost category for reimbursement. AlloSkin AC is a decellularized, meshed, dermis-only skin allograft. The resulting acellular matrix is a favorable microenvironment for bio-ingrowth, acting as a scaffold onto which the body can build dermal tissue through revascularization and cellular repopulation. Acellular dermal tissue is used clinically in the treatment of partial and full-thickness burns, traumatic tissue loss due to injury and for chronic wounds such as pressure ulcers, diabetic foot ulcers and venous and arterial ulcers. AlloSkin AC has Outpatient Medicare reimbursement coverage under the Novitas Administrative Contract. AlloSkin RT has broad clinical applications for acute and chronic wound therapy and is a ready-to-use, shelf-stable graft with room temperature storage. CMS' new high-cost category coverage for AlloSkin RT is a result of new regulations in 2014 for skin substitutes, which are divided into high- and low-cost categories for bundled product and application payment within Hospital Outpatient Departments.

AlloSource Appoints Milo Metcalf as Vice President of Operations

AlloSource announced appointment of Milo Metcalf as Vice President of Operations. Metcalf has more than sixteen years of experience in engineering and operations roles in the global medical device industry. As the Vice President of Operations, Metcalf will oversee several departments at AlloSource, including donor receiving, tissue processing, supply chain, facilities, engineering and materials management. His role ensures all areas of AlloSource's operations maximize the gift of donation to provide life-saving and life-enhancing allografts.

Allosource and Humacyte Inc. Become Strategic Manufacturing Partners to Create Investigational Bioengineered Blood Vessels from Tissue Donor Cells

AlloSource and Humacyte Inc. announced that they have entered into a long-term strategic manufacturing partnership. According to the agreement, AlloSource will become the sole manufacturing partner to create Humacyte's investigational bioengineered blood vessels being developed for hemodialysis applications. Humacyte, a developer of novel human tissue-based products for potential applications in regenerative medicine and vascular surgery, uses innovative technology to create the first investigational biological replacement vessels that are being developed to be stored "off-the-shelf" for future use. Subject to ongoing research and development and future regulatory approval, Humacyte's investigational bioengineered vessels could be used to create a vascular graft option available for patients on demand. These investigational bioengineered vessels are produced using donated human vascular cells and then decellularized to remove the donor identity from the newly created vessels. This process results in the production of investigational human vascular grafts with the potential to be implanted into any patient at the time of medical need.

Similar Private Companies By Industry

Company Name Region
Coram Alternate Site Services, Inc. United States
Rehab Designs of Wisconsin, Inc. United States
First Choice Rehabilitation Specialists PC United States
Milford Regional Medical Center, Inc. United States
Penn Marc Internal Medicine, P.C. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AlloSource, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at